ASLAN003 is primarily investigated for its potential in cancer therapy, particularly in targeting specific pathways involved in tumor growth and survival. It has shown promise in preclinical studies for its ability to inhibit certain kinases, which play a critical role in the proliferation of cancer cells. Researchers are exploring its efficacy in treating solid tumors and hematologic malignancies, with a focus on cancers that are resistant to conventional treatments. Additionally, ASLAN003 is being studied for its potential to enhance the effectiveness of other anticancer therapies when used in combination. Its application extends to personalized medicine, where it could be tailored to patients based on their specific genetic and molecular profiles. Ongoing clinical trials aim to establish its safety, dosage, and therapeutic benefits in human patients.